---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-010864"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T21:59:40.763383+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Trevi: Phase 2 CANAL interim p<0.0001 (52% cough reduction); PRISM enrollment done

## Summary
- Phase 2 CANAL interim analysis: 52% placebo-adjusted reduction in daytime cough events (p<0.0001); enrollment ended early; full data Q3 2022.
- Phase 2b/3 PRISM trial (pruritus in prurigo nodularis) completed enrollment Jan 31, 2022; top-line data expected Q2 2022.
- Q4 2021 net loss $8.5M vs $9.5M in Q4 2020; full-year net loss $33.9M vs $32.8M in 2020.
- Cash and equivalents of $36.8M as of Dec 31, 2021.
- KOL webinar on IPF chronic cough set for March 30, 2022.

## SEC filing metadata
- accession: 0001564590-22-010864
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022010864/0001564590-22-010864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022010864/trvi-8k_20220317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-010864
- JSON: https://secwatch.observer/filing/0001564590-22-010864.json
- Plain text: https://secwatch.observer/filing/0001564590-22-010864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.